Lisata Therapeutics, Inc.
LSTA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000320017
No open-market purchases or sales by Lisata Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $3.70M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Lisata Therapeutics, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 20 | 21 | +1 |
| Shares | 782.5K | 739.2K | −43.3K (−5.5%) |
| Value | $2.26M | $1.93M | −$323.6K (−14.3%) |
New holders (3)
Institutions that held Lisata Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Ground Swell Capital, LLC | 23,774 | $62.3K | 0.14% |
| XTX Topco Ltd | 11,111 | $29.1K | 0.00% |
| Connective Capital Management, LLC | 1,016 | $2.66K | 0.00% |
Sold out (2)
Institutions that held Lisata Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| UBS Group AG | 7,069 | $20.5K |
| Raymond James Financial Inc | 6 | $17 |